Mathematical Biosciences

We consider a general mathematical model for protein subunit vaccine with a focus on the MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2, and use the model to study immunological outcomes in the humoral and cell-mediated arms of the immune response from vaccination. The mathematical model is fit to vaccine clinical trial data. We elucidate the role of Interferon- 𝛾 and Interleukin-4 in stimulating the immune response of the host. Model results, and results from a sensitivity analysis, show that a balance between the T 𝐻 1 and T 𝐻 2 arms of the immune response is struck, with the T 𝐻 1 response being dominant. The model predicts that two-doses of the vaccine at 28 days apart will result in approximately 85% humoral immunity loss relative to peak immunity approximately 6 months post dose 1.

[1]  J. Heffernan,et al.  Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans , 2022, Journal of Mathematical Biology.

[2]  J. Heffernan,et al.  Long-term predictions of humoral immunity after two doses of BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex , 2021, medRxiv.

[3]  J. Heffernan,et al.  Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines , 2021, medRxiv.

[4]  B. Pulendran,et al.  Adjuvanting a subunit COVID-19 vaccine to induce protective immunity , 2021, Nature.

[5]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[6]  H. Andersen,et al.  CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization , 2020, Frontiers in Immunology.

[7]  Kaviyarasi Renu,et al.  The role of Interleukin-4 in COVID-19 associated male infertility – A hypothesis , 2020, Journal of Reproductive Immunology.

[8]  John A. Hangasky,et al.  Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink , 2020, Frontiers in Immunology.

[9]  C. Rice,et al.  Convergent antibody responses to SARS-CoV-2 in convalescent individuals , 2020, Nature.

[10]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[11]  C. Beauchemin,et al.  Progress and trends in mathematical modelling of influenza A virus infections , 2018, Current Opinion in Systems Biology.

[12]  T. Kuribayashi.  Elimination half-lives of interleukin-6 and cytokine-induced neutrophil chemoattractant-1 synthesized in response to inflammatory stimulation in rats , 2018, Laboratory animal research.

[13]  M. Peppelenbosch,et al.  Basal interferon signaling and therapeutic use of interferons in controlling rotavirus infection in human intestinal cells and organoids , 2018, Scientific Reports.

[14]  S. J. Sucheck,et al.  Recent Advances in Subunit Vaccine Carriers , 2016, Vaccines.

[15]  J. Lees.  Interferon gamma in autoimmunity: A complicated player on a complex stage. , 2015, Cytokine.

[16]  Paul G. Thomas,et al.  Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8+ T cells , 2015, Nature Communications.

[17]  P. Chatterjee,et al.  Regulation of the Anti-Inflammatory Cytokines Interleukin-4 and Interleukin-10 during Pregnancy , 2014, Front. Immunol..

[18]  S. Miller,et al.  16 – Helper T-cell subsets and control of the inflammatory response , 2012 .

[19]  Chang-Seon Song,et al.  A review of vaccine development and research for industry animals in Korea. , 2012 .

[20]  E. Kroon,et al.  Basal Activation of Type I Interferons (Alpha2 and Beta) and 2′5′OAS Genes: Insights into Differential Expression Profiles of Interferon System Components in Systemic Sclerosis , 2011, International journal of rheumatology.

[21]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[22]  Christopher D. Paddock,et al.  Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection , 2009, Journal of Virology.

[23]  S. Miller,et al.  Helper T cell subsets and control of the inflammatory response , 2008 .

[24]  H. Käyhty,et al.  Current State of Pneumococcal Vaccines , 2002, Scandinavian journal of immunology.

[25]  J. Lafaille,et al.  The Role of IFN-γ in the Production of Th2 Subpopulations: Implications for Variable Th2-Mediated Pathologies in Autoimmunity1 , 2001, The Journal of Immunology.

[26]  A. Berger.  Th1 and Th2 responses: what are they? , 2000, BMJ : British Medical Journal.

[27]  J. Ragnaud,et al.  Th1 (IL‐2, interferon‐gamma (IFN‐γ)) and Th2 (IL‐10, IL‐4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE) , 1999, Clinical and experimental immunology.

[28]  Paludan.  Interleukin‐4 and Interferon‐γ: The Quintessence of a Mutual Antagonistic Relationship , 1998, Scandinavian journal of immunology.

[29]  D. Remick,et al.  Transcriptional and post-transcriptional regulation of interleukin-8. , 1996, The American journal of pathology.

[30]  T. Barington,et al.  Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. , 1996, The Pediatric infectious disease journal.

[31]  W. Paul,et al.  Lymphocyte responses and cytokines , 1994, Cell.

[32]  S. Akira,et al.  IL‐6 and NF‐IL6 in Acute‐Phase Response and Viral Infection , 1992, Immunological reviews.

[33]  M. Hilleman,et al.  Haemophilus influenzae Type b Polysaccharide-Protein Conjugate Vaccine , 1987, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[34]  J. Davies,et al.  Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.

[35]  B. Gomero.  Latin Hypercube Sampling and Partial Rank Correlation Coefficient Analysis Applied to an Optimal Control Problem , 2012 .

[36]  Moisés Santillán,et al.  On the Use of the Hill Functions in Mathematical Models of Gene Regulatory Networks , 2008 .

[37]  R W Ellis,et al.  New technologies for making vaccines. , 1999, Vaccine.

[38]  Rajesh K. Gupta,et al.  Adjuvants--a balance between toxicity and adjuvanticity. , 1993, Vaccine.

[39]  F. Seiler,et al.  [Structure and function of immunoglobulins]. , 1982, Beitrage zu Infusionstherapie und klinische Ernahrung.